WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, ...

Baseline serum metabolomic profiles may help predict gout flare risk at ULT initiation and identify patients less likely to respond adequately to colchicine prophylaxis.

Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered randomized trial, researchers found. Between acute MI patients randomized to ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Colchicine, an anti-inflammatory drug used to treat gout and rheumatic disease, may be a promising ...

Please provide your email address to receive an email when new articles are posted on . Historical use of colchicine, or its precursors, dates back several thousand years, with reports appearing in ...

AMSTERDAM -- Anti-inflammatory colchicine (Lodoco) given perioperatively around major non-cardiac thoracic surgery did not cut atrial fibrillation (Afib) or myocardial injury complications, the COP-AF ...

Please provide your email address to receive an email when new articles are posted on . Patients taking colchicine had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events.

The open-label, prospective study (GRECCO-19) assessed the effect of treatment with low-dose colchicine on cardiac and inflammatory biomarkers as well as clinical outcomes. Colchicine could ...

Colchicine is one of the oldest medicines with potent anti-inflammatory functions, widely used to treat rheumatic diseases such as gout, calcium pyrophosphate deposition disease (CPDD), and familial ...

Adding colchicine to optimal medical therapy in patients with a recent acute coronary syndrome not only reduces inflammation as measured by high-sensitivity C-reactive protein (hsCRP) but also results ...